Chengdu Gowell Biopharmaceutical

Chengdu Gowell Biopharmaceutical is a prominent Chinese pharmaceutical company focused on the development, manufacturing, and commercialization of high-end generic drugs and innovative therapeutics. Headquartered in Chengdu, the company has established a leading market position in the fields of anesthesia and analgesia, while strategically expanding into cardiovascular health, diabetes, and oncology. Gowell operates multiple R&D centers and state-of-the-art manufacturing facilities that comply with international GMP standards, supporting its goal of globalizing its product portfolio. Since its listing on the Shanghai Stock Exchange STAR Market in 2020, the company has significantly increased its investment in innovative drug discovery, particularly focusing on non-addictive pain management and complex small molecules. The company's business model integrates the stability of high-barrier generics with the high growth potential of a proprietary innovative pipeline.